Algorae Pharmaceuticals Issues New Shares Under Cleansing Notice

Living Cell Technologies ( (AU:1AI) ) just unveiled an announcement.

Algorae Pharmaceuticals has issued new fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and has done so without a prospectus under the disclosure exemptions of the Corporations Act. The company confirms it is up to date with its financial reporting and continuous disclosure obligations, and that there is no excluded information that must be revealed, effectively clearing the way for the newly issued shares to be freely traded and providing assurance to investors about regulatory compliance.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited is an Australian biotechnology company listed on the ASX under the ticker 1AI. The company operates in the pharmaceuticals sector and is focused on developing and commercialising drug-related technologies, targeting investors in the public capital markets for funding its activities.

YTD Price Performance: 14.29%

Average Trading Volume: 1,541,148

Technical Sentiment Signal: Hold

Current Market Cap: A$25.62M

See more insights into 1AI stock on TipRanks’ Stock Analysis page.